TACE加^(32)P-GMS治疗中晚期肝癌疗效分析

目的 探讨肝动脉化疗栓塞 (TACE)加 32 磷—玻璃微球 (32 P- GMS)内照射治疗中晚期肝癌的治疗效果。方法 随机选择 4 8例中晚期肝癌患者分为两组 ,其中 2 3例 (A组 )采用 TACE加 32 P- GMS内放射进行治疗 ;另 2 5例 (B组 )为同期肝动脉化疗栓塞治疗患者 ,做为对照组。两组患者在年龄均数、肿瘤直径以及肿瘤转移率等方面均具有较好的可比性 (P>0 .0 5 )。最后比较两组的治疗效果以及累计生存率。结果 治疗后 3月观察 A组病灶缩小 >5 0 % 5例 ,缩小 <5 0 % 8例 ,有效率为5 6 .5 2 % (13/ 2 3) ,B组 2 8例中有效 9例 (36 % ) ,经 Ridit分析 ,两组有显著性差异 (P<0 .0 5 )。 6个月、12个月、2 4个月 A组生存率分别为 86 .96 %、4 7.83%、2 1.74 % ,而对照组分别为 5 2 %、16 %、0 .0 0 % (P<0 .0 5 )。结论 TACE加 32 P-

Experimental research of relationship between doses and biological effect of ^(32)P-GMS by percutaneous intra-tumor injection to treat liver cancer

Objection： To study the relationship between different doses and biological effect of 32p-glass microspheres （32P-GMS） by percutaneous intra-tumor injection at different times and provide proofs of theory for clinical therapy. Methods： 36 Zealand rabbits and Vx-2 were used to establish the animal model of liver tumor. Six groups were randomly designed. The suspension of different radiative doses of 32p-GMS combined with lipiodol-ultrafluid （0.1 mL） was respectively injected by percutaneous intra-tumor. The tumor tissues were examined by light microscope. MRI examination of liver tumors were performed before and after the injection. Results： C and D groups were observed that the tumor volume was decreased and the rate of restrained tumor was gradually increased after injection of 32p-GMS. The living tumor tissues of E group completely disappeared after the injection for two weeks. MRI examination showed that the tumor signal of E group was equal as T2 as the signal of normal liver parenchyma. The living tumor tissues were not found in F group after the injection for three weeks. Conclusion： 111 MBq was the best radiative dose of ~2p-GMS for treatment of 1 cm liver cancer by percutaneous intra-tumor injection. MRI examination was very valuable to evaluate the result and follow up after the injection to treat liver cancer.

磷［^（32）P］玻璃微球联合加热或平阳霉素的体外抗肿瘤作用

采用集落形成试验，观察了磷［３２Ｐ］玻璃微球（３２Ｐ－ＧＭＳ）联合加热（水浴，４３℃，２０ｍｉｎ）或化疗药物（平阳霉素，终浓度０．０８μｇ／ｍｌ）对人舌鳞状细胞癌Ｔｃａ８１１３的作用。结果表明：３２Ｐ－ＧＭＳ联合加热有协同增敏作用（Ｅ／Ｏ值为１．６３）；联合平阳霉素有相加作用（Ｅ／Ｏ值为１．０１）。

区域注射磷-32玻璃微球对裸鼠移植性人肝细胞癌的形态学影响

目的：研究－３２玻璃微球（３２Ｐ－ＧＭＳ）区域注射对裸鼠移植性人肝细胞癌的形态学影响及其意义。方法：应用光镜、免疫组织化学及电镜观察对照组及治疗组的肿瘤组织学和超微结构特征。结果：对照组中，瘤体长径约３ｃｍ，瘤细胞排列紧密，呈小梁状，富于血窦，约５％瘤细胞坏死。治疗组中，瘤体长径为０．４～２ｃｍ，其中少部分瘤体边缘细胞排列紧密，大部分瘤细胞排列松散，呈网状或假腺样且被纤维血管束分割成巢。４０％～８０％的瘤细胞呈凝固性坏死。７５％以上排列紧密的瘤细胞ＰＣＮＡ阳性，而排列松散的ＰＣＮＡ阳性瘤细胞不足２５％。松散排列的瘤细胞较紧密排列的瘤细胞，桥粒显著减少、细胞变性坏死增多。结论：本研究提示局部内放射３２Ｐ－ＧＭＳ明显具有杀伤癌细胞和抑制肿瘤生长的作用。这为３２Ｐ－ＧＭＳ对肝癌治疗的实验研究和临床应用提供形态学依据。

^(32)磷玻璃微球治疗晚期肝癌

３２磷玻璃微球治疗晚期肝癌华西医科大学附属第一医院（６１００４１）严律南目前国内外已公认肝动脉栓塞疗法是治疗不能切除的晚期肝癌的首选方法［１］。而在众多栓塞材料的比较中，具有内放射作用的材料如１３１Ｉ标记碘化油，１３１Ｉ标记铁蛋白抗体，１３１Ｉ标记丝...

^32P-玻璃微球肝动脉灌注治疗晚期肝癌的初步应用

^32P-玻璃微球(^32P—GMS)是一种新的内放射栓塞荆，作者在动物实验的基础上，自1994．3～1995．4月用该微球治疗晚期肝癌24例。平均年龄44．5岁(21～60岁)。经AFP、酶学、CT或MRI、B超、血管造影及手术活检证实的原发性肝癌22例(其中胆管细胞癌2例)，转移性肝癌2例(结肠恶性淋巴瘤、直肠癌)。Ⅱ期5例，Ⅲ期19例。巨块型13例(瘤体直径均大干10cm，平均12.3cm)，弥漫型4例，结节型7例。